Literature DB >> 23625279

Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there?

Yuefeng Rao1, Feiyue Zheng.   

Abstract

CASE DESCRIPTION: We present a case of a 63-year-old Chinese female who developed severe thrombocytopenia after receiving olsalazine 1.5 g daily for 3 months, and eventually culminated in hospital admission. According to a Medline search, this is the first case report of olsalazine-associated thrombocytopenia in Asia.
CONCLUSION: Olsalazine, similar to other 5-aminosalicylates, can also cause thrombocytopenia. Clinicians should be aware of this potential adverse drug reaction. Future studies should focus on the trigger mechanism and possible cross-reaction between olsalazine and other aminosalicylates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23625279     DOI: 10.1007/s11096-013-9778-8

Source DB:  PubMed          Journal:  Int J Clin Pharm


  10 in total

Review 1.  Advances in the diagnosis of adverse drug reactions.

Authors:  C A Naranjo; N H Shear; K L Lanctôt
Journal:  J Clin Pharmacol       Date:  1992-10       Impact factor: 3.126

2.  Mesalazine-associated thrombocytopenia.

Authors:  T K Daneshmend
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

3.  [Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?].

Authors:  S Braucci; F Trappolini; L Angrisani; E Luberti; A Clarice; M Proietta; D Pisani; M Trappolini
Journal:  Clin Ter       Date:  2007 Jan-Feb

Review 4.  Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?

Authors:  Peter Laszlo Lakatos; Laszlo Lakatos
Journal:  Pharmacol Res       Date:  2008-08-28       Impact factor: 7.658

5.  Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia.

Authors:  D A Gremse; J Bancroft; M S Moyer
Journal:  J Pediatr Gastroenterol Nutr       Date:  1989-08       Impact factor: 2.839

6.  Thrombocytopenia and sulfasalazine.

Authors:  J M Peña; J J Gonzalez-Garcia; J Garcia-Alegria; F J Barbado; J J Vazquez
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

7.  The long journey of salicylates in ulcerative colitis: The past and the future.

Authors:  Renzo Caprilli; Monica Cesarini; Erika Angelucci; Giuseppe Frieri
Journal:  J Crohns Colitis       Date:  2009-05-29       Impact factor: 9.071

8.  Acute interstitial nephritis due to mesalazine.

Authors:  Mario Tadic; Ivica Grgurevic; Mira Scukanec-Spoljar; Borka Bozic; Srecko Marusic; Ivica Horvatic; Kresimir Galesic
Journal:  Nephrology (Carlton)       Date:  2005-04       Impact factor: 2.506

9.  Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.

Authors:  Atsushi Komatsuda; Yohsuke Okamoto; Takashi Hatakeyama; Hideki Wakui; Ken-ichi Sawada
Journal:  Clin Rheumatol       Date:  2007-10-19       Impact factor: 2.980

10.  Sulfasalazine-induced immune thrombocytopenia.

Authors:  L Cantarini; I Tinazzi; D Biasi; A Fioravanti; M Galeazzi
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.